Uterine cancer, also known as endometrial cancer, is a type of cancer that occurs in the lining of the uterus. It is the fourth most common cancer in women, and its incidence is increasing worldwide. The global uterine cancer diagnostic testing market is expected to grow significantly in the coming years due to the increasing incidence of uterine cancer and the growing demand for early diagnosis and treatment.
Market Size and Growth:
The global uterine cancer diagnostic testing market is projected to expand at a CAGR of 7.8% during the forecast period and is expected to be valued at US$ 3,756.8 Mn by the end of 2026. Asia-Pacific market for uterine cancer diagnostic testing is expected to witness siginificant growth in the global uterine cancer diagnostic testing market over the forecast period.
Factors Driving the Market:
The increasing incidence of uterine cancer is one of the key factors driving the market growth. According to the American Cancer Society, about 66,570 new cases of uterine cancer were diagnosed in the United States in 2021, and about 12,940 women died from the disease.
In addition, the growing demand for early diagnosis and treatment is driving the market growth. Early detection of uterine cancer can lead to better treatment outcomes and higher survival rates.
Product Type:
The uterine cancer diagnostic testing market is segmented into imaging tests, biopsy, blood tests, and others. The imaging tests segment is expected to hold the largest share of the market in 2020. This is due to the increasing use of imaging tests, such as ultrasound, MRI, and CT scans, in the diagnosis of uterine cancer.
Application:
The market is segmented into diagnosis and monitoring. The diagnosis segment is expected to hold the largest share of the market in 2020. This is due to the increasing incidence of uterine cancer and the growing demand for early diagnosis and treatment.
Regional Analysis:
North America is expected to hold the largest share of the uterine cancer diagnostic testing market in 2020, followed by Europe. The presence of major market players, increasing government funding for cancer research, and the growing demand for early diagnosis and treatment are driving the growth of the market in these regions. Asia Pacific is expected to be the fastest-growing region in the market due to the increasing incidence of uterine cancer, rising healthcare expenditure, and growing investments in healthcare infrastructure.
Key Players:
The major players operating in the global uterine cancer diagnostic testing market include Roche Diagnostics, Abbott Laboratories, Hologic, Inc., Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, Qiagen N.V., Bio-Rad Laboratories, Inc., and Illumina, Inc.
Order the sample copy of report @ https://www.persistencemarketresearch.com/samples/17005
Conclusion:
The global uterine cancer diagnostic testing market is expected to grow significantly in the coming years due to the increasing incidence of uterine cancer and the growing demand for early diagnosis and treatment. The imaging tests segment is expected to hold the largest share of the market in 2020, and the diagnosis segment is expected to be the largest application segment. North America is expected to hold the largest share of the market in 2020, followed by Europe. The major players operating in the market are Roche Diagnostics, Abbott Laboratories, Hologic, Inc., Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, Qiagen N.V., Bio-Rad Laboratories, Inc., and Illumina, Inc.